(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

With similar 10-year follow-up, there is a trend for improved locoregional control if treated as of 1980. Our data suggest that overall survival is longer for patients treated with IMRT. The current study lends further support to the body of evidence suggesting that in contrast to squamous cell carcinoma of the larynx, overall survival is improving for patients with squamous cell carcinoma of the hypopharynx.

Julian Johnson, MD, Stephen Shiao, MD, PhD, Vivian Weinberg, PhD, Jeanne Quivey, MD, Sue Yom, MD, PhD; University of California, San Francisco; Cedars Sinai

BACKGROUND AND PURPOSE: To determine the effect of treatment decade and utilization of intensity-modulated radiation therapy (IMRT) on locoregional control and overall survival in patients with squamous cell carcinoma of the hypopharynx.

METHODS: Between 1962 and 2008, 116 patients with squamous cell carcinoma of the hypopharynx underwent definitive radiotherapy. We retrospectively reviewed our experience treating these patients with radiotherapy (IMRT, 3-dimensional conformal radiotherapy [3DCRT], intraoperative radiotherapy [IORT], and external beam radiation therapy [EBRT]). This report focuses on the pattern of locoregional control, overall survival, and toxicity rates over the study period. 

RESULTS: Median follow-up duration from diagnosis was 17 months (range: < 2–441 mo). The 2-year estimates of overall survival and locoregional control were 41% (95% confidence interval [CI], 32%–50%) and 55% (95% CI, 44%–65%), respectively. The 5-year estimates of overall survival and locoregional control for the entire patient population were 25% (95% CI, 17%–33%) and 49% (95% CI, 37%–60%), respectively. The median overall survival for all patients was 18.3 months (range: 2–441 mo). With respect to treatment type, the median overall survival with EBRT was 13.8 months, 20.1 months for 3DCRT, and 37.8 months for IMRT (log-rank test: P = .04). Median overall survival estimates by decade were not statistically significantly different: 10.5 months for 1960–1969, 11.3 months for 1970–1979, 18.2 months for 1980–1989, 17.0 months for 1990–1999, and 37.8 months for 2000–2010 (P = .22). There was a trend for improved locoregional control comparing post-1980 treatment to pre-1980 treatment (P = .09) but not for overall survival (P = .52). Treatment with chemotherapy was increasingly more common over the 5 decades studied (P < .001) but did not impact locoregional or survival control (P = .69). Having surgery did not impact overall survival (P = .28) but improved locoregional control, resulting in 2-year and 5-year estimates of 66% vs 48% and 60% vs 41%, respectively (P = .045). The frequency of grade ≥ 3 mucositis decreased over time by decade (P = .01), whereas dysphagia did not. Data on xerostomia were not consistently recorded. 

CONCLUSIONS: With similar 10-year follow-up, there is a trend for improved locoregional control if treated as of 1980. Our data suggest that overall survival is longer for patients treated with IMRT. Our data also suggest that toxicity from mucositis has declined over time. The current study lends further support to the body of evidence suggesting that in contrast to squamous cell carcinoma of the larynx, overall survival is improving for patients with squamous cell carcinoma of the hypopharynx. 

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content